Catalent to Manufacture J&J's Covid-19 Vaccine Candidate
April 29 2020 - 9:32AM
Dow Jones News
By Colin Kellaher
Catalent Inc. on Wednesday said it will serve as a manufacturer
for Johnson & Johnson's lead vaccine candidate for
Covid-19.
The Somerset, N.J., contract drug maker said it will prepare for
large-scale commercial manufacturing of the vaccine at its plant in
Bloomington, Ind.
The company said it will invest jointly with J&J to
accelerate rapid scale-up of segregated manufacturing capacity over
the coming months to support dedicated production of the
vaccine.
Catalent said it plans to hire about 300 new employees at the
site starting in July 2020 to meet around-the-clock manufacturing
schedules by January 2021.
Johnson & Johnson, which was among the first companies to
announce a Covid-19 vaccine development program back in January,
has said it aims to supply more than one billion doses of the
vaccine globally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 29, 2020 09:17 ET (13:17 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024